Jazz Pharmaceuticals (JAZZ) said Friday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for zanidatamab to treat adults with unresectable locally advanced or metastatic HER2-positive biliary tract cancer.
The recommendation for the conditional marketing authorization of the investigational monotherapy in the European Union is backed by data from a phase 2b trial of patients previously treated with systemic therapy, according to the biopharmaceutical company.
The European Commission is expected to make a final decision based on the Committee's recommendation, Jazz Pharmaceuticals said.
JAZZ shares were edging 0.6% higher in recent trading.
Price: 109.58, Change: +0.60, Percent Change: +0.55
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.